Literature DB >> 14981344

Genetics and pathophysiology of hyperinsulinism in infancy.

Karen E Cosgrove1, Ruth M Shepherd, Eva M Fernandez, Anuja Natarajan, Keith J Lindley, Albert Aynsley-Green, Mark J Dunne.   

Abstract

Hyperinsulinism in infancy (HI) is a condition of neonates and early childhood. For many years the pathophysiology of this potentially lethal disorder was unknown. Advances in the genetics, histopathology and molecular physiology of this disease have now provided insights into the causes of beta-cell dysfunction and revealed levels of diversity far in excess of our previous knowledge. These include defects in ion channel subunit genes and mutations in several enzymes associated with beta-cell metabolism and anaplerosis. In most cases, beta-cell pathophysiology leads to an alteration in the function of ATP-sensitive K(+) channels. This can manifest as 'channelopathies' of K(ATP) channels through gene defects in ABCC8 and KCNJ11 (Ch.11p15); or as a result of 'metabolopathies' through defects in the genes encoding glucokinase (GCK, Ch.7p15-p13), glutamate dehydrogenase (GLUD1, Ch.10q23.3) and short-chain L-3-hydroxyacyl-CoA dehydrogenase (HADHSC, Ch.4q22-q26). This review focuses upon the relationship between the causes of HI and therapeutic options. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14981344     DOI: 10.1159/000076933

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  3 in total

Review 1.  K(ATP) channelopathies in the pancreas.

Authors:  Maria S Remedi; Joseph C Koster
Journal:  Pflugers Arch       Date:  2009-11-18       Impact factor: 3.657

Review 2.  Neonatal diabetes mellitus.

Authors:  Lydia Aguilar-Bryan; Joseph Bryan
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

Review 3.  The value of radiologic interventions and (18)F-DOPA PET in diagnosing and localizing focal congenital hyperinsulinism: systematic review and meta-analysis.

Authors:  Björn A Blomberg; Mateen C Moghbel; Babak Saboury; Charles A Stanley; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2013-02       Impact factor: 3.488

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.